Results 171 to 180 of about 137,002 (346)

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Regulation of Insulin Secretion Through Long‐Chain Fatty Acid Receptors

iNew Medicine, EarlyView.
Stefan Offermanns
wiley   +1 more source

Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes

The Laryngoscope, EarlyView.
ABSTRACT Objective The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population.
Praneet C. Kaki, Troy Wesson, Alison Choi, Sophia Shah, Thomas Kaffenberger, Ryan Soose, Noah Parker, Maurits Boon, Colin Huntley, Chihun Jim Han   +9 more
wiley   +1 more source

Once-weekly glucagon-like peptide 1 receptor agonists.

JPMA. The Journal of the Pakistan Medical Association, 2015
The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

A case report on the long‐term use of teduglutide in a pediatric patient with short bowel syndrome

Nutrition in Clinical Practice, EarlyView.
Abstract Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long‐term parenteral nutrition (PN). Teduglutide (TED), a glucagon‐like peptide‐2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long‐term data in pediatric populations remain limited.
Tsuyoshi Sakurai, Hironori Kudo, Nakamura Megumi, Ryo Ando, Takuro Kazama, Ryuji Okubo, Masatoshi Hashimoto, Ko Minoshima, Motoshi Wada   +8 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Circulation, 2008
Kiwon Ban, Kiwon Ban, M. H. Noyan-Ashraf, M. H. Noyan-Ashraf, J. Hoefer, J. Hoefer, S. Bolz, D. J. Drucker, D. J. Drucker, M. Husain, M. Husain   +10 more
semanticscholar   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source